9/23/04

FILE 'REGISTRY' ENTERED AT 15:01:45 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L1 STRUCTURE UPLOADED

10607930

9/23/04

=> d l1
L1 HAS NO ANSWERS
L1 STR





G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:02:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 113848 TO ITERATE

0.9% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str





9/23/04

ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS

10607930

9/23/04

L3 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 15:04:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 42968 TO ITERATE

2.3% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 846997 TO 871723
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> logoff y\
'Y\' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> logoff y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 2.94 3.15

STN INTERNATIONAL LOGOFF AT 15:05:50 ON 22 SEP 2004

Connecting via Winsock to STN

9/23/04

Welcome to STN International! Enter x:x

LOGINID:ssspta1612rxd

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 4	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 5	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 6	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 7	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 8	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS 9	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 10	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 11	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 12	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 13	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 14	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:11:52 ON 22 SEP 2004

=>
=>

9/23/04

Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:12:07 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17 16-17
exact/norm bonds :

10607930

9/23/04

1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:12:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 307 TO ITERATE

100.0% PROCESSED 307 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5089 TO 7191
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful

9/23/04

FULL SEARCH INITIATED 15:12:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6161 TO ITERATE

100.0% PROCESSED 6161 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 15:12:33 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d abs bib hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the $\alpha 4\beta 2$ subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H

and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646055-65-4P**, 1-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646055-65-4 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 1-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **646055-61-0P**, 1-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane

dihydrochloride **646056-36-2P**, 7-Methyl-1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)

RN 646055-61-0 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 1-(3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 646056-36-2 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **646055-64-3P**, tert-Butyl 6-(3-pyridyl)-2,6-diazaspiro[4.4]nonane-2-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)

RN 646055-64-3 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane-7-carboxylic acid, 1-(3-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

9/23/04



=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.64	161.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.70	-0.70

FILE 'REGISTRY' ENTERED AT 15:13:48 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



9/23/04

ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 15:14:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 44 TO ITERATE

100.0% PROCESSED 44 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS:          483 TO     1277
PROJECTED ANSWERS:               2 TO      124

L6             2 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 15:14:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    881 TO ITERATE

100.0% PROCESSED     881 ITERATIONS                          19 ANSWERS
SEARCH TIME: 00.00.01

L7            19 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 155.42     316.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -0.70

FILE 'CAPLUS' ENTERED AT 15:14:19 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Sep 2004  VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004  (20040921/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l7
L8             8 L7

=> d abs bib fhitstr 1-8

L8   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2004 ACS on STN
GI
```



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the $\alpha 4\beta 2$ subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H

and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646056-44-2P**, 2-(3-Pyridyl)-2,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646056-44-2 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Title compds. [I; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkylalkyl, aralkyl, etc.; R1R2N = 4-11 membered (bridged) (substituted) heterocyclyl; R3, R4 = H, halo, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, OR7, N(R7)2, cyano, etc.; R3R4 = atoms to form 5-7 membered (substituted) ring; R5 = H, halo, alkyl, perfluoroalkyl, OR7, N(R7)2; R6 = (CH2)nR7, (CH2)nCN, (CH2)nCO2R7, (CH2)nOR7, (CH2)nN(R7)2, etc.; R7 = H, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, aralkenyl, cycloalkylalkenyl, etc.; n = 0-5], were prepared for the treatment or prevention of obesity, eating disorders, osteoarthritis, cancer, AIDS wasting, cachexia, frailty, mental disorders, stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Thus, 2-piperidin-1-ylquinolin-6-amine and (2E)-3-(4-chlorophenyl)prop-2-enoyl chloride were stirred 3 h in HOAc to give (2E)-3-(4-chlorophenyl)-N-(2-piperidin-1-ylquinolin-6-yl)prop-2-enamide hydrochloride. I bound to MCH-1R receptors with IC50 = 0.1-10000 nM.

AN 2003:434303 CAPLUS

DN 139:36445

TI Preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists.

IN Devita, Robert J.; Chang, Lehua; Chaung, Danny; Hoang, Myle; Jiang, Jinlong; Lin, Peter; Sailer, Andreas W.; Young, Jonathan R.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045313	A2	20030605	WO 2002-US37556	20021122
	WO 2003045313	A3	20030904		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1450801	A2	20040901	EP 2002-789837	20021122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRAI US 2001-333581P P 20011127
WO 2002-US37556 W 20021122

OS MARPAT 139:36445

IT **539852-73-8P**, N-[2-(7-Methyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of 2-aminoquinolines as melanin concentrating hormone
receptor (MCH-1R) antagonists)

RN 539852-73-8 CAPLUS

CN Benzenepropanamide, N-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AB The errors were not reflected in the abstract or the index entries.

AN 1995:2483 CAPLUS

DN 123:164953

TI Anti-mycobacterium avium activity of quinolones: in vitro activities. [Erratum to document cited in CA120:27300f]

AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian, Saralee; Edmonds, Kay; Ellner, Jerrold J.

CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA

SO Antimicrobial Agents and Chemotherapy (1993), 37(12), 2766
CODEN: AMACCQ; ISSN: 0066-4804

DT Journal

LA English

IT **91188-27-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mycobacterium avium sensitivity to (Erratum))

RN 91188-27-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AB The MICs of 88 quinolones against 14 selected reference and clin. strains of Mycobacterium avium-M. intracellulare complex were determined Agents tested included ciprofloxacin, sparfloxacin (PD 131501), and 86 other exptl. quinolones. Test strains were selected to represent various susceptibilities to ciprofloxacin and other drug resistance profiles. MICs were determined by the microdilution method in 7HSF broth, with incubation for 14 days at 35°. The results showed 25 of the quinolones to be active against the strains, with MICs for 90% of the strains (MIC90s) of 2 to 32 μg/mL. Ten of these compds. had activities equivalent to or greater than that of ciprofloxacin. The most active compound was PD 125354, with an MIC50 of 0.5 μg/mL and an MIC90 of 2 μg/mL; comparable values for ciprofloxacin were 4 and 8 μg/mL, resp. The next most active compds., with MIC90s of 4 μg/mL, were sparfloxacin (PD 131501), PD 123982, PD 135144, and PD 119421. MIC90s of PD 131575, PD 126889, PD 122642, PD 139586, and PD 143289 were 8 μg/mL. Further evaluation of the most active agents is warranted, as is assessment of structure-activity relationships of active and inactive agents to elucidate the active portions of the compds. and to lead to the development of compds. with enhanced activity.

AN 1994:27300 CAPLUS
DN 120:27300

TI Anti-mycobacterium avium activity of quinolones: in vitro activities

AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian, Saralee; Edmonds, Kay; Ellner, Jerrold J.
CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA

SO Antimicrobial Agents and Chemotherapy (1993), 37(9), 1799-806
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

IT **91188-27-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Mycobacterium avium sensitivity to)

RN 91188-27-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB Fluoroquinolone antibacterials having the 7-position (10-position of pyridobenzoxazines) substituted with 2,7-diazaspiro[4.4]nonane, 1,7-diazaspiro[4.4]nonane, or 2,8-diazaspiro[5.5]undecane (e.g. I (X = CF, CH, N) were prepared and their biol. activities were compared with piperazine and pyrrolidine substituted analogs. Most exhibited potent Gram-pos. and Gram-neg. activity, especially when side chain was N-alkylated. Thus, the quinolinecarboxylic acid II was treated with 2-methyl-2,7-diazaspiro[4.4]nonane to give I (X = CH).

AN 1990:497432 CAPLUS
DN 113:97432
TI Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships
AU Culbertson, Townley P.; Sanchez, Joseph P.; Gambino, Laura; Sesnie, Josephine A.
CS Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48105, USA
SO Journal of Medicinal Chemistry (1990), 33(8), 2270-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 113:97432
IT **91188-27-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI


I


II

AB The title compds. [I; A = N, CR9; R1 = Me, Et, cyclopropyl, etc.; R2 = H, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R3 = Me, 13 N-attached heterocyclyl; R9 = H, halo, Me, cyano, NO2; R1R9 = OCH2CHMe, SCH2CHMe, CH2CH2CHMe] were prepared C6F5COCH2CO2Et (preparation given) was refluxed 2 h with HC(OEt)3 in Ac2O to give C6F5COC(CO2Et):CHOEt which was treated overnight with cyclopropylamine in EtOH to give C6F5COC(CO2Et):CHNHR (R = cyclopropyl). The latter was refluxed 3 h in DMF containing NaF to give, after saponification, quinolonecarboxylate II (R3 = Y = F) which was refluxed 3 h with 1-methylpiperazine in MeCN/DMF containing Dabco to give II (R3 = 4-methyl-1-piperazinyl, Y = F) (III). Tablets were prepared each containing III 583.0, cellulose 55.0, starch 72.0, polyvinylpyrrolidone 30.0, SiO2 5.0, and Mg stearate 5.0 mg with a coating comprising (hydroxypropyl)methylcellulose 6.0, Macrogol 40,000 2.0, and TiO2 2.0 mg. II (R3 = 3-methyl-1-piperazinyl, Y = NH2) had a min. inhibitory concentration of 0.5 (units not given) against Escherichia coli 455/7.

AN 1989:114697 CAPLUS
DN 110:114697
TI Preparation of 5-substituted quinolone- and naphthyridonecarboxylic acids as antibacterial agents
IN Petersen, Uwe; Grohe, Klaus; Schriewer, Michael; Schenke, Thomas; Haller, Ingo; Metzger, Karl; Endermann, Rainer; Zeiler, Hans Joachim
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 32 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3711193	A1	19881013	DE 1987-3711193	19870402
	NO 8801121	A	19881003	NO 1988-1121	19880314
	EP 284935	A1	19881005	EP 1988-104452	19880321
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	AU 8813811	A1	19881006	AU 1988-13811	19880328
	DD 274029	A5	19891206	DD 1988-314159	19880329
	DK 8801802	A	19881003	DK 1988-1802	19880330
	FI 8801501	A	19881003	FI 1988-1501	19880330
	CN 88101741	A	19881116	CN 1988-101741	19880331

	ZA 8802318	A	19881228	ZA 1988-2318	19880331
	JP 63258855	A2	19881026	JP 1988-78298	19880401
	HU 47098	A2	19890130	HU 1988-1619	19880401
	HU 201050	B	19900928		
PRAI	DE 1987-3711193		19870402		

OS CASREACT 110:114697; MARPAT 110:114697

IT **119354-28-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial agent)

RN 119354-28-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 5-amino-1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

GI



I



II

AB The title compds. (I; X = FC, N; R1 = H, alkyl, cation; R2 = amino, heterocyclyl) were prepared Thus, 2,3,4,5-F4C6HCO2H was converted to its acid chloride and condensed with EtO2CCH2CO2H to give 2,3,4,5-F4C6HCOCH2CO2H. This was cyclocondensed with (EtO)3CH and cyclopropylamine to give I (X = FC, R1 = H, R2 = F). The latter was treated with 3-pyrrolidinemethanamine to give 7-[3-(aminomethyl)-1-pyrrolidinyl]-3-quinolinecarboxylic acid derivative II. II had a min. inhibitory concentration of <0.1 μg/mL against, e.g., Escherichia coli Vogel.

AN 1986:34013 CAPLUS

DN 104:34013

TI 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their derivatives

IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols,

Jeffrey B.
PA Warner-Lambert Co. , USA
SO Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 153163	A2	19850828	EP 1985-301009	19850215
	EP 153163	A3	19860129		
	EP 153163	B1	19891227		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4665079	A	19870512	US 1985-692820	19850123
	ZA 8500854	A	19860924	ZA 1985-854	19850204
	CA 1289956	A1	19911001	CA 1985-473502	19850204
	IL 74286	A1	19880731	IL 1985-74286	19850208
	AU 8538618	A1	19850822	AU 1985-38618	19850211
	AU 568004	B2	19871210		
	DK 8500687	A	19850818	DK 1985-687	19850214
	DK 161889	B	19910826		
	DK 161889	C	19920203		
	FI 8500631	A	19850818	FI 1985-631	19850215
	FI 83312	B	19910315		
	FI 83312	C	19910625		
	NO 8500614	A	19850819	NO 1985-614	19850215
	NO 161370	B	19890502		
	NO 161370	C	19890809		
	JP 60214773	A2	19851028	JP 1985-26669	19850215
	JP 07055945	B4	19950614		
	HU 37149	O	19851128	HU 1985-580	19850215
	ES 540441	A1	19870501	ES 1985-540441	19850215
	AT 48997	E	19900115	AT 1985-301009	19850215
	JP 07173160	A2	19950711	JP 1994-278595	19941019
PRAI	US 1984-581157		19840217		
	US 1985-692820		19850123		
	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1985-301009		19850215		

OS CASREACT 104:34013
IT **91188-24-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)
RN 91188-24-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Title compds. I and II [R = H, halo; R1 = (un)substituted N heterocycle; R2 = alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, vinyl; R3 = H, alkyl, cation; R4, R5 = H, alkyl; Z = H, (un)substituted CH] were prepared Thus, II (R = R1 = F, R3 = R4 = H, R5 = Me) was treated with diazaspirononane III.2HCl, prepared from Et 3-(ethoxycarbonyl)-5-oxo-3-pyrrolidineacetate, to give II (R = 7-methyl-2,7-diazaspiro[4,4]non-2-yl), which had a min. inhibitory concentration against Staphylococcus aureus UC-76 of 0.006 μg/mL.

AN 1984:472740 CAPLUS

DN 101:72740

TI Antibacterial agents

IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols, Jeffrey B.

PA Warner-Lambert Co. , USA

SO Eur. Pat. Appl., 125 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 106489	A2	19840425	EP 1983-305148	19830906
	EP 106489	A3	19850424		
	EP 106489	B1	19880727		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ZA 8306357	A	19840425	ZA 1983-6357	19830826
	IL 69601	A1	19870831	IL 1983-69601	19830830
	IL 80848	A1	19880930	IL 1983-80848	19830830
	IL 80849	A1	19881031	IL 1983-80849	19830830
	FI 8303151	A	19840310	FI 1983-3151	19830905

	FI 83513	B	19910415		
	FI 83513	C	19910725		
	AU 8318698	A1	19840315	AU 1983-18698	19830905
	AU 562286	B2	19870604		
	AT 35987	E	19880815	AT 1983-305148	19830906
	CS 246065	B2	19861016	CS 1983-6498	19830907
	DK 8304074	A	19840310	DK 1983-4074	19830908
	DK 171098	B1	19960603		
	NO 8303206	A	19840312	NO 1983-3206	19830908
	NO 164418	B	19900625		
	NO 164418	C	19901003		
	JP 59067269	A2	19840416	JP 1983-164271	19830908
	JP 07042284	B4	19950510		
	HU 31718	O	19840528	HU 1983-3140	19830908
	HU 196986	B	19890228		
	DD 216010	A5	19841128	DD 1983-254624	19830908
	ES 525493	A1	19850116	ES 1983-525493	19830908
	SU 1360584	A3	19871215	SU 1983-3659624	19831103
	ES 529934	A1	19850601	ES 1984-529934	19840222
	ES 529936	A1	19850616	ES 1984-529936	19840222
	ES 529937	A1	19850616	ES 1984-529937	19840222
	ES 529935	A1	19850701	ES 1984-529935	19840222
	ES 529933	A1	19851016	ES 1984-529933	19840222
	SU 1321376	A3	19870630	SU 1984-3732809	19840427
	SU 1314954	A3	19870530	SU 1984-3736502	19840503
	CS 246083	B2	19861016	CS 1984-4630	19840618
	CS 246084	B2	19861016	CS 1984-4631	19840618
	CS 247180	B2	19861218	CS 1984-4632	19840618
	JP 01146880	A2	19890608	JP 1988-282640	19881110
	JP 04210961	A2	19920803	JP 1991-53587	19910227
	JP 06062561	B4	19940817		
	JP 07070111	A2	19950314	JP 1994-32109	19940302
	JP 07080770	B4	19950830		
	DK 9400700	A	19940616	DK 1994-70094	19940616
	DK 170471	B1	19950911	DK 1994-700	19940616
	JP 08311061	A2	19961126	JP 1996-134697	19960529
	JP 2704984	B2	19980126		
PRAI	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1983-305148		19830906		
	CS 1983-6498		19830907		
	JP 1983-164271		19830908		

IT **91188-24-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 91188-24-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



=> d abs bib hitstr 1-8

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving

Blank Sheet (USPTO)

neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the α4β2 subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646056-44-2P**, 2-(3-Pyridyl)-2,7-diazaspiro[4.4]nonane
646056-52-2P, 2-(5-Methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane

646056-53-3P, 2-[5-(Cyclopentyloxy)-3-pyridyl]-2,7-diazaspiro[4.4]nonane **646056-54-4P**, 2-(5-Phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane **646056-55-5P**, 2-[5-(4-Hydroxyphenoxy)-3-pyridyl]-2,7-diazaspiro[4.4]nonane **646056-56-6P**, 2-(5-Ethynyl-3-pyridyl)-2,7-diazaspiro[4.4]nonane **646056-57-7P**, 2-(6-Chloro-3-pyridyl)-2,7-diazaspiro[4.4]nonane **646056-59-9P**, 2-Methyl-7-(3-pyridyl)-2,7-diazaspiro[4.4]nonane **646056-60-2P**, 2-Methyl-7-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane **646056-61-3P**, 2-Methyl-7-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)

RN 646056-44-2 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-52-2 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(5-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-53-3 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-[5-(cyclopentyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 646056-54-4 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(5-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-55-5 CAPLUS
CN Phenol, 4-[[5-(2,7-diazaspiro[4.4]non-2-yl)-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 646056-56-6 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(5-ethynyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-57-7 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(6-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-59-9 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-methyl-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 646056-60-2 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-(5-methoxy-3-pyridinyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 646056-61-3 CAPLUS
CN 2,7-Diazaspiro[4.4]nonane, 2-methyl-7-(5-phenoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Title compds. [I; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl,

cycloalkylalkyl, aralkyl, etc.; R1R2N = 4-11 membered (bridged) (substituted) heterocyclyl; R3, R4 = H, halo, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, OR7, N(R7)2, cyano, etc.; R3R4 = atoms to form 5-7 membered (substituted) ring; R5 = H, halo, alkyl, perfluoroalkyl, OR7, N(R7)2; R6 = (CH2)nR7, (CH2)nCN, (CH2)nCO2R7, (CH2)nOR7, (CH2)nN(R7)2, etc.; R7 = H, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, aralkenyl, cycloalkylalkenyl, etc.; n = 0-5], were prepared for the treatment or prevention of obesity, eating disorders, osteoarthritis, cancer, AIDS wasting, cachexia, frailty, mental disorders, stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Thus, 2-piperidin-1-ylquinolin-6-amine and (2E)-3-(4-chlorophenyl)prop-2-enoyl chloride were stirred 3 h in HOAc to give (2E)-3-(4-chlorophenyl)-N-(2-piperidin-1-ylquinolin-6-yl)prop-2-enamide hydrochloride. I bound to MCH-1R receptors with IC50 = 0.1-10000 nM.

AN 2003:434303 CAPLUS
DN 139:36445
TI Preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists.
IN Devita, Robert J.; Chang, Lehua; Chaung, Danny; Hoang, Myle; Jiang, Jinlong; Lin, Peter; Sailer, Andreas W.; Young, Jonathan R.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045313	A2	20030605	WO 2002-US37556	20021122
	WO 2003045313	A3	20030904		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1450801	A2	20040901	EP 2002-789837	20021122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-333581P	P	20011127		
	WO 2002-US37556	W	20021122		

OS MARPAT 139:36445
IT **539852-73-8P**, N-[2-(7-Methyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide **539852-75-0P**, N-[2-(7-Benzyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide **539852-77-2P**, N-[2-(2,7-Diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(claimed compound; preparation of 2-aminoquinolines as melanin concentrating hormone
receptor (MCH-1R) antagonists)
RN 539852-73-8 CAPLUS
CN Benzenepropanamide, N-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 539852-75-0 CAPLUS
CN Benzenepropanamide, N-[2-[7-(phenylmethyl)-2,7-diazaspiro[4.4]non-2-yl]-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 539852-77-2 CAPLUS
CN Benzenepropanamide, N-[2-(2,7-diazaspiro[4.4]non-2-yl)-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AB The errors were not reflected in the abstract or the index entries.
AN 1995:2483 CAPLUS
DN 123:164953
TI Anti-mycobacterium avium activity of quinolones: in vitro activities. [Erratum to document cited in CA120:27300f]
AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian,

Saralee; Edmonds, Kay; Ellner, Jerrold J.
CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA
SO Antimicrobial Agents and Chemotherapy (1993), 37(12), 2766
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
IT **91188-27-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mycobacterium avium sensitivity to (Erratum))
RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AB The MICs of 88 quinolones against 14 selected reference and clin. strains of Mycobacterium avium-M. intracellulare complex were determined Agents tested included ciprofloxacin, sparfloxacin (PD 131501), and 86 other exptl. quinolones. Test strains were selected to represent various susceptibilities to ciprofloxacin and other drug resistance profiles. MICs were determined by the microdilution method in 7HSF broth, with incubation for 14 days at 35°. The results showed 25 of the quinolones to be active against the strains, with MICs for 90% of the strains (MIC90s) of 2 to 32 μg/mL. Ten of these compds. had activities equivalent to or greater than that of ciprofloxacin. The most active compound was PD 125354, with an MIC50 of 0.5 μg/mL and an MIC90 of 2 μg/mL; comparable values for ciprofloxacin were 4 and 8 μg/mL, resp. The next most active compds., with MIC90s of 4 μg/mL, were sparfloxacin (PD 131501), PD 123982, PD 135144, and PD 119421. MIC90s of PD 131575, PD 126889, PD 122642, PD 139586, and PD 143289 were 8 μg/mL. Further evaluation of the most active agents is warranted, as is assessment of structure-activity relationships of active and inactive agents to elucidate the active portions of the compds. and to lead to the development of compds. with enhanced activity.
AN 1994:27300 CAPLUS
DN 120:27300
TI Anti-mycobacterium avium activity of quinolones: in vitro activities
AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian, Saralee; Edmonds, Kay; Ellner, Jerrold J.
CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA
SO Antimicrobial Agents and Chemotherapy (1993), 37(9), 1799-806
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
IT **91188-27-1**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Mycobacterium avium sensitivity to)

RN 91188-27-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

GI



AB Fluoroquinolone antibacterials having the 7-position (10-position of pyridobenzoxazines) substituted with 2,7-diazaspiro[4.4]nonane, 1,7-diazaspiro[4.4]nonane, or 2,8-diazaspiro[5.5]undecane (e.g. I (X = CF, CH, N) were prepared and their biol. activities were compared with piperazine and pyrrolidine substituted analogs. Most exhibited potent Gram-pos. and Gram-neg. activity, especially when side chain was N-alkylated. Thus, the quinolinecarboxylic acid II was treated with 2-methyl-2,7-diazaspiro[4.4]nonane to give I (X = CH).

AN 1990:497432 CAPLUS

DN 113:97432

TI Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships

AU Culbertson, Townley P.; Sanchez, Joseph P.; Gambino, Laura; Sesnie, Josephine A.

CS Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48105, USA

SO Journal of Medicinal Chemistry (1990), 33(8), 2270-5
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 113:97432

IT **91188-27-1P 91188-34-0P 91196-83-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91196-83-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB The title compds. [I; A = N, CR9; R1 = Me, Et, cyclopropyl, etc.; R2 = H, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R3 = Me, 13 N-attached heterocyclyl; R9 = H, halo, Me, cyano, NO2; R1R9 = OCH2CHMe, SCH2CHMe, CH2CH2CHMe] were prepared C6F5COCH2CO2Et (preparation given) was refluxed 2 h with HC(OEt)3 in Ac2O to give C6F5COC(CO2Et):CHOEt which was treated overnight with cyclopropylamine in EtOH to give C6F5COC(CO2Et):CHNHR (R = cyclopropyl). The latter was refluxed 3 h in DMF containing NaF to give, after saponification, quinolonecarboxylate II (R3 = Y = F) which was refluxed 3 h with 1-methylpiperazine in MeCN/DMF containing Dabco to give II (R3 = 4-methyl-1-piperazinyl, Y = F) (III). Tablets were prepared each containing III 583.0, cellulose 55.0, starch 72.0, polyvinylpyrrolidone 30.0, SiO2 5.0, and Mg stearate 5.0 mg with a coating comprising (hydroxypropyl)methylcellulose 6.0, Macrogol 40,000 2.0, and TiO2 2.0 mg. II (R3 = 3-methyl-1-piperazinyl, Y = NH2) had a min. inhibitory concentration of 0.5 (units not given) against Escherichia coli 455/7.

AN 1989:114697 CAPLUS

DN 110:114697

TI Preparation of 5-substituted quinolone- and naphthyridonecarboxylic acids as antibacterial agents

IN Petersen, Uwe; Grohe, Klaus; Schriewer, Michael; Schenke, Thomas; Haller, Ingo; Metzger, Karl; Endermann, Rainer; Zeiler, Hans Joachim

PA Bayer A.-G., Fed. Rep. Ger.

SO Ger. Offen., 32 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3711193	A1	19881013	DE 1987-3711193	19870402
	NO 8801121	A	19881003	NO 1988-1121	19880314
	EP 284935	A1	19881005	EP 1988-104452	19880321
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	AU 8813811	A1	19881006	AU 1988-13811	19880328
	DD 274029	A5	19891206	DD 1988-314159	19880329
	DK 8801802	A	19881003	DK 1988-1802	19880330
	FI 8801501	A	19881003	FI 1988-1501	19880330
	CN 88101741	A	19881116	CN 1988-101741	19880331
	ZA 8802318	A	19881228	ZA 1988-2318	19880331

	JP 63258855	A2	19881026	JP 1988-78298	19880401
	HU 47098	A2	19890130	HU 1988-1619	19880401
	HU 201050	B	19900928		
PRAI	DE 1987-3711193		19870402		

OS CASREACT 110:114697; MARPAT 110:114697

IT **119354-28-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial agent)

RN 119354-28-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 5-amino-1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

GI



I



II

AB The title compds. (I; X = FC, N; R1 = H, alkyl, cation; R2 = amino, heterocyclyl) were prepared Thus, 2,3,4,5-F4C6HCO2H was converted to its acid chloride and condensed with EtO2CCH2CO2H to give 2,3,4,5-F4C6HCOCH2CO2H. This was cyclocondensed with (EtO)3CH and cyclopropylamine to give I (X = FC, R1 = H, R2 = F). The latter was treated with 3-pyrrolidinemethanamine to give 7-[3-(aminomethyl)-1-pyrrolidinyl]-3-quinolinecarboxylic acid derivative II. II had a min. inhibitory concentration of <0.1 μg/mL against, e.g., Escherichia coli Vogel.

AN 1986:34013 CAPLUS

DN 104:34013

TI 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their derivatives

IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols, Jeffrey B.

PA Warner-Lambert Co. , USA
SO Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 153163	A2	19850828	EP 1985-301009	19850215
	EP 153163	A3	19860129		
	EP 153163	B1	19891227		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4665079	A	19870512	US 1985-692820	19850123
	ZA 8500854	A	19860924	ZA 1985-854	19850204
	CA 1289956	A1	19911001	CA 1985-473502	19850204
	IL 74286	A1	19880731	IL 1985-74286	19850208
	AU 8538618	A1	19850822	AU 1985-38618	19850211
	AU 568004	B2	19871210		
	DK 8500687	A	19850818	DK 1985-687	19850214
	DK 161889	B	19910826		
	DK 161889	C	19920203		
	FI 8500631	A	19850818	FI 1985-631	19850215
	FI 83312	B	19910315		
	FI 83312	C	19910625		
	NO 8500614	A	19850819	NO 1985-614	19850215
	NO 161370	B	19890502		
	NO 161370	C	19890809		
	JP 60214773	A2	19851028	JP 1985-26669	19850215
	JP 07055945	B4	19950614		
	HU 37149	O	19851128	HU 1985-580	19850215
	ES 540441	A1	19870501	ES 1985-540441	19850215
	AT 48997	E	19900115	AT 1985-301009	19850215
	JP 07173160	A2	19950711	JP 1994-278595	19941019
PRAI	US 1984-581157		19840217		
	US 1985-692820		19850123		
	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1985-301009		19850215		

OS CASREACT 104:34013
IT **91188-24-8P 91188-27-1P 91188-34-0P**
99734-94-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)
RN 91188-24-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 99734-94-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Title compds. I and II [R = H, halo; R1 = (un)substituted N heterocycle; R2 = alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, vinyl; R3 = H, alkyl, cation; R4, R5 = H, alkyl; Z = H, (un)substituted CH] were prepared Thus, II (R = R1 = F, R3 = R4 = H, R5 = Me) was treated with diazaspirononane III.2HCl, prepared from Et 3-(ethoxycarbonyl)-5-oxo-3-pyrrolidineacetate, to give II (R = 7-methyl-2,7-diazaspiro[4,4]non-2-yl), which had a min. inhibitory concentration against Staphylococcus aureus UC-76 of 0.006 μg/mL.

AN 1984:472740 CAPLUS

DN 101:72740

TI Antibacterial agents

IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols, Jeffrey B.

PA Warner-Lambert Co. , USA

SO Eur. Pat. Appl., 125 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 106489	A2	19840425	EP 1983-305148	19830906
	EP 106489	A3	19850424		
	EP 106489	B1	19880727		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ZA 8306357	A	19840425	ZA 1983-6357	19830826
	IL 69601	A1	19870831	IL 1983-69601	19830830
	IL 80848	A1	19880930	IL 1983-80848	19830830
	IL 80849	A1	19881031	IL 1983-80849	19830830
	FI 8303151	A	19840310	FI 1983-3151	19830905
	FI 83513	B	19910415		
	FI 83513	C	19910725		
	AU 8318698	A1	19840315	AU 1983-18698	19830905
	AU 562286	B2	19870604		
	AT 35987	E	19880815	AT 1983-305148	19830906
	CS 246065	B2	19861016	CS 1983-6498	19830907

	DK 8304074	A	19840310	DK 1983-4074	19830908
	DK 171098	B1	19960603		
	NO 8303206	A	19840312	NO 1983-3206	19830908
	NO 164418	B	19900625		
	NO 164418	C	19901003		
	JP 59067269	A2	19840416	JP 1983-164271	19830908
	JP 07042284	B4	19950510		
	HU 31718	O	19840528	HU 1983-3140	19830908
	HU 196986	B	19890228		
	DD 216010	A5	19841128	DD 1983-254624	19830908
	ES 525493	A1	19850116	ES 1983-525493	19830908
	SU 1360584	A3	19871215	SU 1983-3659624	19831103
	ES 529934	A1	19850601	ES 1984-529934	19840222
	ES 529936	A1	19850616	ES 1984-529936	19840222
	ES 529937	A1	19850616	ES 1984-529937	19840222
	ES 529935	A1	19850701	ES 1984-529935	19840222
	ES 529933	A1	19851016	ES 1984-529933	19840222
	SU 1321376	A3	19870630	SU 1984-3732809	19840427
	SU 1314954	A3	19870530	SU 1984-3736502	19840503
	CS 246083	B2	19861016	CS 1984-4630	19840618
	CS 246084	B2	19861016	CS 1984-4631	19840618
	CS 247180	B2	19861218	CS 1984-4632	19840618
	JP 01146880	A2	19890608	JP 1988-282640	19881110
	JP 04210961	A2	19920803	JP 1991-53587	19910227
	JP 06062561	B4	19940817		
	JP 07070111	A2	19950314	JP 1994-32109	19940302
	JP 07080770	B4	19950830		
	DK 9400700	A	19940616	DK 1994-70094	19940616
	DK 170471	B1	19950911	DK 1994-700	19940616
	JP 08311061	A2	19961126	JP 1996-134697	19960529
	JP 2704984	B2	19980126		
PRAI	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1983-305148		19830906		
	CS 1983-6498		19830907		
	JP 1983-164271		19830908		

IT **91188-24-8P 91188-27-1P 91188-34-0P 91196-83-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of)

RN 91188-24-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91196-83-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

9/23/04

FULL ESTIMATED COST 77.48 394.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE -11.20 -11.90

FILE 'REGISTRY' ENTERED AT 15:16:02 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17 16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

10607930

9/23/04

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str





ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

9/23/04

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l10
SAMPLE SEARCH INITIATED 15:20:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 44 TO ITERATE

100.0% PROCESSED 44 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 483 TO 1277
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 ful
FULL SEARCH INITIATED 15:20:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 881 TO ITERATE

100.0% PROCESSED 881 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L12 9 SEA SSS FUL L10

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

9/23/04

FULL ESTIMATED COST	158.36	552.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-11.90

FILE 'CAPLUS' ENTERED AT 15:20:47 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L13 7 L12

=> s l13 not l8
L14 0 L13 NOT L8

=> d abs bib hitstr l13 1-7

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Title compds. [I; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkylalkyl, aralkyl, etc.; R1R2N = 4-11 membered (bridged) (substituted) heterocyclyl; R3, R4 = H, halo, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, OR7, N(R7)2, cyano, etc.; R3R4 = atoms to form 5-7 membered (substituted) ring; R5 = H, halo, alkyl, perfluoroalkyl, OR7, N(R7)2; R6 = (CH2)nR7, (CH2)nCN, (CH2)nCO2R7, (CH2)nOR7, (CH2)nN(R7)2,

etc.; R7 = H, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, aralkenyl, cycloalkylalkenyl, etc.; n = 0-5], were prepared for the treatment or prevention of obesity, eating disorders, osteoarthritis, cancer, AIDS wasting, cachexia, frailty, mental disorders, stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Thus, 2-piperidin-1-ylquinolin-6-amine and (2E)-3-(4-chlorophenyl)prop-2-enoyl chloride were stirred 3 h in HOAc to give (2E)-3-(4-chlorophenyl)-N-(2-piperidin-1-ylquinolin-6-yl)prop-2-enamide hydrochloride. I bound to MCH-1R receptors with IC50 = 0.1-10000 nM.

AN 2003:434303 CAPLUS
DN 139:36445
TI Preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists.
IN Devita, Robert J.; Chang, Lehua; Chaung, Danny; Hoang, Myle; Jiang, Jinlong; Lin, Peter; Sailer, Andreas W.; Young, Jonathan R.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045313	A2	20030605	WO 2002-US37556	20021122
	WO 2003045313	A3	20030904		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1450801	A2	20040901	EP 2002-789837	20021122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-333581P	P	20011127		
	WO 2002-US37556	W	20021122		

OS MARPAT 139:36445
IT **539852-73-8P**, N-[2-(7-Methyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide **539852-75-0P**, N-[2-(7-Benzyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide **539852-77-2P**, N-[2-(2,7-Diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists)
RN 539852-73-8 CAPLUS
CN Benzenepropanamide, N-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-6-

quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 539852-75-0 CAPLUS
CN Benzenepropanamide, N-[2-[7-(phenylmethyl)-2,7-diazaspiro[4.4]non-2-yl]-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 539852-77-2 CAPLUS
CN Benzenepropanamide, N-[2-(2,7-diazaspiro[4.4]non-2-yl)-6-quinolinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AB The errors were not reflected in the abstract or the index entries.
AN 1995:2483 CAPLUS
DN 123:164953
TI Anti-mycobacterium avium activity of quinolones: in vitro activities. [Erratum to document cited in CA120:27300f]
AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian, Saralee; Edmonds, Kay; Ellner, Jerrold J.
CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA
SO Antimicrobial Agents and Chemotherapy (1993), 37(12), 2766
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

IT **91188-27-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mycobacterium avium sensitivity to (Erratum))
RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AB The MICs of 88 quinolones against 14 selected reference and clin. strains of Mycobacterium avium-M. intracellulare complex were determined Agents tested included ciprofloxacin, sparfloxacin (PD 131501), and 86 other exptl. quinolones. Test strains were selected to represent various susceptibilities to ciprofloxacin and other drug resistance profiles. MICs were determined by the microdilution method in 7HSF broth, with incubation for 14 days at 35°. The results showed 25 of the quinolones to be active against the strains, with MICs for 90% of the strains (MIC90s) of 2 to 32 μg/mL. Ten of these compds. had activities equivalent to or greater than that of ciprofloxacin. The most active compound was PD 125354, with an MIC50 of 0.5 μg/mL and an MIC90 of 2 μg/mL; comparable values for ciprofloxacin were 4 and 8 μg/mL, resp. The next most active compds., with MIC90s of 4 μg/mL, were sparfloxacin (PD 131501), PD 123982, PD 135144, and PD 119421. MIC90s of PD 131575, PD 126889, PD 122642, PD 139586, and PD 143289 were 8 μg/mL. Further evaluation of the most active agents is warranted, as is assessment of structure-activity relationships of active and inactive agents to elucidate the active portions of the compds. and to lead to the development of compds. with enhanced activity.
AN 1994:27300 CAPLUS
DN 120:27300
TI Anti-mycobacterium avium activity of quinolones: in vitro activities
AU Klopman, Gilles; Wang, Shaomeng; Jacobs, Michael R.; Bajaksouzian, Saralee; Edmonds, Kay; Ellner, Jerrold J.
CS Chem. Dep., Case West. Reserve Univ., Cleveland, OH, 44106, USA
SO Antimicrobial Agents and Chemotherapy (1993), 37(9), 1799-806
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
IT **91188-27-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Mycobacterium avium sensitivity to)
RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I II

AB Fluoroquinolone antibacterials having the 7-position (10-position of pyridobenzoxazines) substituted with 2,7-diazaspiro[4.4]nonane, 1,7-diazaspiro[4.4]nonane, or 2,8-diazaspiro[5.5]undecane (e.g. I (X = CF, CH, N) were prepared and their biol. activities were compared with piperazine and pyrrolidine substituted analogs. Most exhibited potent Gram-pos. and Gram-neg. activity, especially when side chain was N-alkylated. Thus, the quinolinecarboxylic acid II was treated with 2-methyl-2,7-diazaspiro[4.4]nonane to give I (X = CH).

AN 1990:497432 CAPLUS

DN 113:97432

TI Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships

AU Culbertson, Townley P.; Sanchez, Joseph P.; Gambino, Laura; Sesnie, Josephine A.

CS Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48105, USA

SO Journal of Medicinal Chemistry (1990), 33(8), 2270-5
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 113:97432

IT **91188-27-1P 91188-34-0P 91196-83-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 91188-27-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91196-83-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB The title compds. [I; A = N, CR9; R1 = Me, Et, cyclopropyl, etc.; R2 = H, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R3 = Me, 13 N-attached heterocyclyl; R9 = H, halo, Me, cyano, NO2; R1R9 = OCH2CHMe, SCH2CHMe, CH2CH2CHMe] were prepared C6F5COCH2CO2Et (preparation given) was refluxed 2 h with HC(OEt)3 in Ac2O to give C6F5COC(CO2Et):CHOEt which was treated overnight with cyclopropylamine in EtOH to give C6F5COC(CO2Et):CHNHR (R = cyclopropyl). The latter was refluxed 3 h in DMF containing NaF to give, after saponification, quinolonecarboxylate II (R3 = Y = F) which was refluxed 3 h with 1-methylpiperazine in MeCN/DMF containing Dabco to give II (R3 = 4-methyl-1-piperazinyl, Y = F) (III). Tablets were prepared each containing III 583.0, cellulose 55.0, starch 72.0, polyvinylpyrrolidone 30.0, SiO2 5.0, and Mg stearate 5.0 mg with a coating comprising (hydroxypropyl)methylcellulose 6.0, Macrogol 40,000 2.0, and TiO2 2.0 mg. II (R3 = 3-methyl-1-piperazinyl, Y = NH2) had a min. inhibitory concentration of 0.5 (units not given) against Escherichia coli 455/7.

AN 1989:114697 CAPLUS

DN 110:114697

TI Preparation of 5-substituted quinolone- and naphthyridonecarboxylic acids as antibacterial agents

IN Petersen, Uwe; Grohe, Klaus; Schriewer, Michael; Schenke, Thomas; Haller, Ingo; Metzger, Karl; Endermann, Rainer; Zeiler, Hans Joachim

PA Bayer A.-G., Fed. Rep. Ger.

SO Ger. Offen., 32 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3711193	A1	19881013	DE 1987-3711193	19870402
	NO 8801121	A	19881003	NO 1988-1121	19880314
	EP 284935	A1	19881005	EP 1988-104452	19880321
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	AU 8813811	A1	19881006	AU 1988-13811	19880328
	DD 274029	A5	19891206	DD 1988-314159	19880329
	DK 8801802	A	19881003	DK 1988-1802	19880330
	FI 8801501	A	19881003	FI 1988-1501	19880330
	CN 88101741	A	19881116	CN 1988-101741	19880331
	ZA 8802318	A	19881228	ZA 1988-2318	19880331
	JP 63258855	A2	19881026	JP 1988-78298	19880401
	HU 47098	A2	19890130	HU 1988-1619	19880401
	HU 201050	B	19900928		
PRAI	DE 1987-3711193		19870402		

OS CASREACT 110:114697; MARPAT 110:114697
IT **119354-28-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial agent)
RN 119354-28-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 5-amino-1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB The title compds. (I; X = FC, N; R1 = H, alkyl, cation; R2 = amino, heterocyclyl) were prepared Thus, 2,3,4,5-F4C6HCO2H was converted to its acid chloride and condensed with EtO2CCH2CO2H to give 2,3,4,5-F4C6HCOCH2CO2H. This was cyclocondensed with (EtO)3CH and cyclopropylamine to give I (X = FC, R1 = H, R2 = F). The latter was treated with 3-pyrrolidinemethanamine to give 7-[3-(aminomethyl)-1-pyrrolidinyl]-3-quinolinecarboxylic acid derivative II. II had a min. inhibitory concentration of <0.1 μg/mL against, e.g., Escherichia coli Vogel.
AN 1986:34013 CAPLUS
DN 104:34013
TI 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their derivatives
IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols, Jeffrey B.
PA Warner-Lambert Co. , USA
SO Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 153163	A2	19850828	EP 1985-301009	19850215
	EP 153163	A3	19860129		
	EP 153163	B1	19891227		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4665079	A	19870512	US 1985-692820	19850123
	ZA 8500854	A	19860924	ZA 1985-854	19850204
	CA 1289956	A1	19911001	CA 1985-473502	19850204
	IL 74286	A1	19880731	IL 1985-74286	19850208
	AU 8538618	A1	19850822	AU 1985-38618	19850211
	AU 568004	B2	19871210		
	DK 8500687	A	19850818	DK 1985-687	19850214
	DK 161889	B	19910826		
	DK 161889	C	19920203		
	FI 8500631	A	19850818	FI 1985-631	19850215
	FI 83312	B	19910315		
	FI 83312	C	19910625		
	NO 8500614	A	19850819	NO 1985-614	19850215
	NO 161370	B	19890502		
	NO 161370	C	19890809		
	JP 60214773	A2	19851028	JP 1985-26669	19850215
	JP 07055945	B4	19950614		
	HU 37149	O	19851128	HU 1985-580	19850215
	ES 540441	A1	19870501	ES 1985-540441	19850215
	AT 48997	E	19900115	AT 1985-301009	19850215
	JP 07173160	A2	19950711	JP 1994-278595	19941019
PRAI	US 1984-581157		19840217		
	US 1985-692820		19850123		
	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1985-301009		19850215		

OS CASREACT 104:34013

IT **91188-24-8P 91188-27-1P 91188-34-0P**
99734-94-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)

RN 91188-24-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-27-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 99734-94-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L13 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Title compds. I and II [R = H, halo; R1 = (un)substituted N heterocycle; R2 = alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, vinyl; R3 = H, alkyl, cation; R4, R5 = H, alkyl; Z = H, (un)substituted CH] were prepared Thus, II (R = R1 = F, R3 = R4 = H, R5 = Me) was treated with diazaspirononane III.2HCl, prepared from Et 3-(ethoxycarbonyl)-5-oxo-3-pyrrolidineacetate, to give II (R = 7-methyl-2,7-diazaspiro[4,4]non-2-yl), which had a min. inhibitory concentration against Staphylococcus aureus UC-76 of 0.006 μg/mL.

AN 1984:472740 CAPLUS

DN 101:72740

TI Antibacterial agents

IN Culbertson, Townley P.; Mich, Thomas F.; Domagala, John M.; Nichols, Jeffrey B.

PA Warner-Lambert Co. , USA

SO Eur. Pat. Appl., 125 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 106489	A2	19840425	EP 1983-305148	19830906
	EP 106489	A3	19850424		
	EP 106489	B1	19880727		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ZA 8306357	A	19840425	ZA 1983-6357	19830826
	IL 69601	A1	19870831	IL 1983-69601	19830830
	IL 80848	A1	19880930	IL 1983-80848	19830830
	IL 80849	A1	19881031	IL 1983-80849	19830830
	FI 8303151	A	19840310	FI 1983-3151	19830905
	FI 83513	B	19910415		
	FI 83513	C	19910725		
	AU 8318698	A1	19840315	AU 1983-18698	19830905
	AU 562286	B2	19870604		
	AT 35987	E	19880815	AT 1983-305148	19830906
	CS 246065	B2	19861016	CS 1983-6498	19830907
	DK 8304074	A	19840310	DK 1983-4074	19830908
	DK 171098	B1	19960603		

	NO 8303206	A	19840312	NO 1983-3206	19830908
	NO 164418	B	19900625		
	NO 164418	C	19901003		
	JP 59067269	A2	19840416	JP 1983-164271	19830908
	JP 07042284	B4	19950510		
	HU 31718	O	19840528	HU 1983-3140	19830908
	HU 196986	B	19890228		
	DD 216010	A5	19841128	DD 1983-254624	19830908
	ES 525493	A1	19850116	ES 1983-525493	19830908
	SU 1360584	A3	19871215	SU 1983-3659624	19831103
	ES 529934	A1	19850601	ES 1984-529934	19840222
	ES 529936	A1	19850616	ES 1984-529936	19840222
	ES 529937	A1	19850616	ES 1984-529937	19840222
	ES 529935	A1	19850701	ES 1984-529935	19840222
	ES 529933	A1	19851016	ES 1984-529933	19840222
	SU 1321376	A3	19870630	SU 1984-3732809	19840427
	SU 1314954	A3	19870530	SU 1984-3736502	19840503
	CS 246083	B2	19861016	CS 1984-4630	19840618
	CS 246084	B2	19861016	CS 1984-4631	19840618
	CS 247180	B2	19861218	CS 1984-4632	19840618
	JP 01146880	A2	19890608	JP 1988-282640	19881110
	JP 04210961	A2	19920803	JP 1991-53587	19910227
	JP 06062561	B4	19940817		
	JP 07070111	A2	19950314	JP 1994-32109	19940302
	JP 07080770	B4	19950830		
	DK 9400700	A	19940616	DK 1994-70094	19940616
	DK 170471	B1	19950911	DK 1994-700	19940616
	JP 08311061	A2	19961126	JP 1996-134697	19960529
	JP 2704984	B2	19980126		
PRAI	US 1982-416406		19820909		
	US 1983-522275		19830812		
	IL 1983-69601		19830830		
	EP 1983-305148		19830906		
	CS 1983-6498		19830907		
	JP 1983-164271		19830908		

IT **91188-24-8P 91188-27-1P 91188-34-0P 91196-83-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 91188-24-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-27-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(7-

methyl-2,7-diazaspiro[4.4]non-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 91188-34-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-7-(7-ethyl-2,7-diazaspiro[4.4]non-2-yl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 91196-83-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(2,7-diazaspiro[4.4]non-2-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.08	587.61

9/23/04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.90	-16.80

FILE 'REGISTRY' ENTERED AT 15:23:20 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17 16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

9/23/04

L15 STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l15
SAMPLE SEARCH INITIATED 15:23:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 307 TO ITERATE

100.0% PROCESSED 307 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5089 TO 7191
PROJECTED ANSWERS: 0 TO 0

L16 0 SEA SSS SAM L15

=> a l15 ful
A IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l15 ful
FULL SEARCH INITIATED 15:23:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6161 TO ITERATE

100.0% PROCESSED 6161 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

10607930

L17 4 SEA SSS FUL L15

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	743.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.80

FILE 'CAPLUS' ENTERED AT 15:23:52 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l17
L18 1 L17

=> d abs bib fhitstr

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the α4β2 subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H

and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646055-65-4P**, 1-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646055-65-4 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 1-(3-pyridinyl)- (9CI) (CA INDEX NAME)



9/23/04

```
=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.64     748.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.70     -17.50

FILE 'REGISTRY' ENTERED AT 15:25:14 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 SEP 2004  HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES:  21 SEP 2004  HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str
```




```
ring nodes :
1  2  3  4  5  6  7  8  9  10  13  14  15  16  17
ring bonds :
1-4  1-2  1-13  1-14  2-3  3-4  5-6  5-10  6-7  7-8  8-9  9-10  13-16  14-15  15-17
16-17
exact/norm bonds :
1-4  1-2  1-13  1-14  2-3  3-4  13-16  14-15  15-17  16-17
normalized bonds :
5-6  5-10  6-7  7-8  8-9  9-10

G1:C,N

10607930
```

9/23/04

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L19 STRUCTURE UPLOADED

=> d l19
L19 HAS NO ANSWERS
L19 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l19
SAMPLE SEARCH INITIATED 15:25:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 436 TO 1204
PROJECTED ANSWERS: 0 TO 0

L20 0 SEA SSS SAM L19

=> s l19 ful
FULL SEARCH INITIATED 15:25:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 605 TO ITERATE

100.0% PROCESSED 605 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

9/23/04

L21 0 SEA SSS FUL L19

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L22 STRUCTURE UPLOADED

=> d l22
L22 HAS NO ANSWERS
L22 STR

9/23/04



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l22
SAMPLE SEARCH INITIATED 15:26:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    307 TO ITERATE

100.0% PROCESSED     307 ITERATIONS                          2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         5089 TO     7191
PROJECTED ANSWERS:               2 TO      124

L23            2 SEA SSS SAM L22

=> s l22 ful
FULL SEARCH INITIATED 15:26:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   6161 TO ITERATE

100.0% PROCESSED    6161 ITERATIONS                         40 ANSWERS
SEARCH TIME: 00.00.01

L24           40 SEA SSS FUL L22

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 311.26    1059.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00     -17.50

FILE 'CAPLUS' ENTERED AT 15:26:57 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

9/23/04

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l24
L25 2 L24

=> d abs bib fhitstr 1-2

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

10607930

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the α4β2 subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

US 2004067930 A1 20040408 US 2003-607930 20030627
PRAI US 2002-394337P P 20020705
OS MARPAT 140:111404
IT **646055-99-4P**, (+)-7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646055-99-4 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB The title compds. (I; X = N or C-Rx, with Rx =H, halogen; R1, R2 = H, halogen; R3 = H, carboxyl; R4 = oxo, OH; R5 = H, amino; R6 = substituted cyclic amino groups) and their physiol. acceptable salts are claimed as antitumor drugs. Thus, I were prepared, and their antitumor activities were

tested in animal models.
AN 1997:594555 CAPLUS
DN 127:288165
TI Antitumor compounds
IN Tomita, Kyoji; Chiba, Katsumi; Kashimoto, Shigeki; Nakada, Katsuhisa; Shibamori, Koichiro; Chikugi, Yasutomo; Tajima, Masanori; Oue, Tomio
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 74 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09221424	A2	19970826	JP 1996-351948	19961210

PRAI JP 1995-347310 19951213
OS MARPAT 127:288165
IT **196821-77-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor compds.)
RN 196821-77-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-7-(9-methylene-1,7-diazaspiro[4.4]non-7-yl)-4-oxo-1-(2-thiazolyl)- (9CI) (CA INDEX NAME)



=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.96	1069.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.40	-18.90

FILE 'REGISTRY' ENTERED AT 15:27:35 ON 22 SEP 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

9/23/04

DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.84	1070.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.90

FILE 'REGISTRY' ENTERED AT 15:28:33 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str



10607930

9/23/04

ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L26 STRUCTURE UPLOADED

=> d l26
L26 HAS NO ANSWERS
L26 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l26
SAMPLE SEARCH INITIATED 15:28:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 307 TO ITERATE

100.0% PROCESSED 307 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5089 TO 7191

PROJECTED ANSWERS: 2 TO 124

L27 2 SEA SSS SAM L26

=> s l26 ful
FULL SEARCH INITIATED 15:28:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6161 TO ITERATE

100.0% PROCESSED 6161 ITERATIONS 40 ANSWERS
SEARCH TIME: 00.00.01

L28 40 SEA SSS FUL L26

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	1226.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.90

FILE 'CAPLUS' ENTERED AT 15:29:04 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l28
L29 2 L28

=> d abs bib fhitstr 1-2

L29 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the $\alpha 4\beta 2$ subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H

and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646055-99-4P**, (+)-7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646055-99-4 CAPLUS
CN 1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



L29 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB The title compds. (I; X = N or C-Rx, with Rx =H, halogen; R1, R2 = H, halogen; R3 = H, carboxyl; R4 = oxo, OH; R5 = H, amino; R6 = substituted cyclic amino groups) and their physiol. acceptable salts are claimed as antitumor drugs. Thus, I were prepared, and their antitumor activities were tested in animal models.

AN 1997:594555 CAPLUS
DN 127:288165
TI Antitumor compounds
IN Tomita, Kyoji; Chiba, Katsumi; Kashimoto, Shigeki; Nakada, Katsuhisa; Shibamori, Koichiro; Chikugi, Yasutomo; Tajima, Masanori; Oue, Tomio
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 74 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09221424	A2	19970826	JP 1996-351948	19961210
PRAI JP 1995-347310		19951213		

OS MARPAT 127:288165
IT **196821-77-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor compds.)
RN 196821-77-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-7-(9-methylene-1,7-diazaspiro[4.4]non-7-yl)-4-oxo-1-(2-thiazolyl)- (9CI) (CA INDEX NAME)

9/23/04



=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.96	1236.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.40	-20.30

FILE 'REGISTRY' ENTERED AT 15:29:32 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES: 21 SEP 2004 HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str





10607930

9/23/04

ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L30 STRUCTURE UPLOADED

=> d l30
L30 HAS NO ANSWERS
L30 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l30
SAMPLE SEARCH INITIATED 15:30:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

9/23/04

```
100.0% PROCESSED      41 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          436 TO     1204
PROJECTED ANSWERS:               0 TO        0

L31           0 SEA SSS SAM L30

=> s l30 ful
FULL SEARCH INITIATED 15:31:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    605 TO ITERATE

100.0% PROCESSED     605 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L32           0 SEA SSS FUL L30

=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     157.52    1393.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -20.30

FILE 'REGISTRY' ENTERED AT 15:33:11 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 SEP 2004  HIGHEST RN 749178-43-6
DICTIONARY FILE UPDATES:  21 SEP 2004  HIGHEST RN 749178-43-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str
```

9/23/04





ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17
ring bonds :
1-4 1-2 1-13 1-14 2-3 3-4 5-6 5-10 6-7 7-8 8-9 9-10 13-16 14-15 15-17
16-17
exact/norm bonds :
1-4 1-2 1-13 1-14 2-3 3-4 13-16 14-15 15-17 16-17
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L33 STRUCTURE UPLOADED

=> d l33
L33 HAS NO ANSWERS
L33 STR

9/23/04



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l33 ful
FULL SEARCH INITIATED 15:33:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    811 TO ITERATE

100.0% PROCESSED     811 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L34            0 SEA SSS FUL L33

=>
Uploading C:\Stnexp4 corrupted\QUERIES\10607930.str
```






```
ring nodes :
1  2  3  4  5  6  7  8  9  10  13  14  15  16  17
ring bonds :
1-4  1-2  1-13  1-14  2-3  3-4  5-6  5-10  6-7  7-8  8-9  9-10  13-16  14-15  15-17
16-17
exact/norm bonds :
1-4  1-2  1-13  1-14  2-3  3-4  13-16  14-15  15-17  16-17
```

10607930

9/23/04

normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L35 STRUCTURE UPLOADED

=> d l35
L35 HAS NO ANSWERS
L35 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l35
SAMPLE SEARCH INITIATED 15:35:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 574 TO ITERATE

100.0% PROCESSED 574 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10043 TO 12917
PROJECTED ANSWERS: 0 TO 0

L36 0 SEA SSS SAM L35

=> s l35 ful
FULL SEARCH INITIATED 15:35:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11554 TO ITERATE

9/23/04

100.0% PROCESSED 11554 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L37 2 SEA SSS FUL L35

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	311.68	1705.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-20.30

FILE 'CAPLUS' ENTERED AT 15:35:18 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l37
L38 1 L37

=> d abs bib fhitstr

L38 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II



III

AB Compds., pharmaceutical compns. including the compds., and methods of preparation and use thereof are disclosed. The compds. are N-aryl diazaspirocyclic compds. (shown as I and II; variables defined below; e.g. III), bridged analogs of N-heteroaryl diazaspirocyclic compds., or prodrugs or metabolites of these compds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compds. and compns. can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which were characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compds. and compns. can also be used to alleviate pain. The compds. can alter the number of nicotinic cholinergic receptors of the brain of the patient, exhibit neuroprotective effects and when employed in effective amts., not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant neg. effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). For the α4β2 subtype, the Ki value for each of the examples of I was <1 μM, indicating that I bind tightly to the receptor. Although the methods of preparation are not claimed, 13 example prepns. are included. For example, III was prepared in 5 steps (76, 93, 96, 66 and 88 % yields, resp.) starting from Et (S)-N-benzylpyrrolidine-2-carboxylate and nitroethylene and involving intermediates Et 2-(2-nitroethyl)-1-benzylpyrrolidine-2-carboxylate, 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one, 1-benzyl-1,7-diazaspiro[4.4]nonane and 1-benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane. For I: Q1 is (CZ2)u; QII is (CZ2)v; QIII is (CZ2)w; and QIV is (CZ2)x; u, v, w and x are individually 0-4, preferably 0-3; R is H, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl; Z is H

and (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, arylalkyl; Cy is a six membered ring linked via C to the N of the rest of I and each of the remaining ring atoms = N, N bonded to O or C bonded to a substituent species, wherein ≤3 are N or N bonded to O, or Cy is a five 5-membered heteroarom. ring linked via C to the N of the rest of I; addnl. details are given in the claims. For II: QV = (CZ2)y; QVI = (CZ2)z; y and z = 0-4; the bridged diazaspirocyclic ring contains 8-13 members; the rest of the variables are defined similarly to those for I.

AN 2004:41475 CAPLUS
DN 140:111404
TI Preparation of N-aryl diazaspirocyclic compounds as nicotinic cholinergic receptor modulators for treating nervous system and other disorders
IN Bhatti, Balwinder S.; Miller, Craig H.; Schmidt, Jeffrey D.
PA Targacept, Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005293	A2	20040115	WO 2003-US20524	20030627
	WO 2004005293	A3	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067930	A1	20040408	US 2003-607930	20030627
PRAI	US 2002-394337P	P	20020705		

OS MARPAT 140:111404
IT **646056-68-0P**, 2-(3-Pyridyl)-2,5-diazaspiro[3.5]nonane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-aryl diazaspirocyclic compds. as nicotinic cholinergic receptor modulators for treating nervous system and other disorders)
RN 646056-68-0 CAPLUS
CN 2,5-Diazaspiro[3.5]nonane, 2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



(NONANE OR NONANES)
L2 84 (1013-88-3/BI OR 108-95-2/BI OR 125552-89-8/BI OR 128244-01-9/BI OR 15761-39-4/BI OR 15833-61-1/BI OR 165253-29-2/BI OR 17117-17-8/BI OR 184849-49-8/BI OR 28232-63-5/BI OR 29943-42-8/BI OR 39926-11-9/BI OR 4595-59-9/BI OR 5680-79-5/BI OR 625-92-3/BI OR 626-35-7/BI OR 626-55-1/BI OR 646055-57-4/BI OR 646055-58-5/BI OR 646055-59-6/BI OR 646055-60-9/BI OR 646055-61-0/BI OR 646055-62-1/BI OR 646055-63-2/BI OR 646055-64-3/BI OR 646055-65-4/BI OR 646055-66-5/BI OR 646055-67-6/BI OR 646055-68-7/BI OR 646055-69-8/BI OR 646055-70-1/BI OR 646055-71-2/BI OR 646055-72-3/BI OR 646055-73-4/BI OR 646055-74-5/BI OR 646055-75-6/BI OR 646055-78-9/BI OR 646055-79-0/BI OR 646055-80-3/BI OR 646055-81-4/BI OR 646055-82-5/BI OR 646055-83-6/BI OR 646055-84-7/BI OR 646055-85-8/BI OR 646055-86-9/BI OR 646055-87-0/BI OR 646055-88-1/BI OR 646055-89-2/BI OR 646055-90-5/BI OR 646055-91-6/BI OR 646055-92-7/BI OR 646055-93-8/BI OR 646055-94-9/BI OR 646055-95-0/BI OR 646055-96-1/BI OR 646055-97-2/BI OR 6460

=> d l2 1-84

compds of application

L2 ANSWER 1 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-69-1** REGISTRY
CN **2,5-Diazaspiro[3.5]nonane, 5-methyl-2-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **5-Methyl-2-(3-pyridyl)-2,5-diazaspiro[3.5]nonane**
MF C13 H19 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-68-0** REGISTRY
CN **2,5-Diazaspiro[3.5]nonane, 2-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(3-Pyridyl)-2,5-diazaspiro[3.5]nonane**
MF C12 H17 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-67-9** REGISTRY
CN **1,6-Diazaspiro[3.5]nonane, 1-methyl-6-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-6-(3-pyridyl)-1,6-diazaspiro[3.5]nonane**
FS 3D CONCORD
MF C13 H19 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-66-8** REGISTRY
CN **1,6-Diazaspiro[3.5]nonane, 6-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **6-(3-Pyridyl)-1,6-diazaspiro[3.5]nonane**
FS 3D CONCORD
MF C12 H17 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-61-3** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-methyl-7-(5-phenoxy-3-pyridinyl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-Methyl-7-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C19 H23 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-60-2** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-methoxy-3-pyridinyl)-7-methyl-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-Methyl-7-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD

MF C14 H21 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-59-9** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-methyl-7-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-Methyl-7-(3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H19 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-58-8** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(6-methoxy-3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(6-Methoxy-3-pyridazinyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD

MF C12 H18 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-57-7** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(6-chloro-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(6-Chloro-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H16 Cl N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-56-6** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-ethynyl-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(5-Ethynyl-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C14 H17 N3
SR CA

LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-55-5** REGISTRY
CN Phenol, 4-[[5-(2,7-diazaspiro[4.4]non-2-yl)-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **2-[5-(4-Hydroxyphenoxy)-3-pyridyl]-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C18 H21 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-54-4** REGISTRY

CN **2,7-Diazaspiro[4.4]nonane, 2-(5-phenoxy-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(5-Phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C18 H21 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-53-3** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-[5-(cyclopentyloxy)-3-pyridinyl]- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-[5-(Cyclopentyloxy)-3-pyridyl]-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C17 H25 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-52-2** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-methoxy-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(5-Methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H19 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-51-1** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(3-Pyridazinyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-50-0** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-pyrazinyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(2-Pyrazinyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 17 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-49-7** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(1,3,4-oxadiazol-2-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-([1,3,4]Oxadiazol-2-yl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN

RN **646056-48-6** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(1,2,4-oxadiazol-5-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-([1,2,4]Oxadiazol-5-yl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-47-5** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-isothiazolyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(5-Isothiazolyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-46-4** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-isoxazolyl)- (9CI)** (CA INDEX NAME)

OTHER NAMES:
CN **2-(5-Isoxazolyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 21 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-45-3** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(5-pyrimidinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(5-Pyrimidinyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-44-2** REGISTRY
CN **2,7-Diazaspiro[4.4]nonane, 2-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-(3-Pyridyl)-2,7-diazaspiro[4.4]nonane**
FS 3D CONCORD

MF C12 H17 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-43-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-42-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-pyrazinyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:

CN **7-Methyl-1-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-41-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(1,3,4-oxadiazol-2-yl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-([1,3,4]oxadiazol-2-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H16 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 26 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-40-8** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(1,2,4-oxadiazol-5-yl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-([1,2,4]oxadiazol-5-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H16 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 27 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-39-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(5-isothiazolyl)-7-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H17 N3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 28 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-38-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(5-isoxazolyl)-7-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H17 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-37-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(5-pyrimidinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 30 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-36-2** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-methyl-1-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-Methyl-1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H19 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 31 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-35-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(6-methoxy-3-pyridazinyl)-1-methyl-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(6-methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H20 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 32 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-34-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(6-chloro-3-pyridinyl)-1-methyl-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(6-chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H18 Cl N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 33 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-33-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-ethynyl-3-pyridinyl)-1-methyl-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C15 H19 N3
SR CA

LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 34 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-32-8** REGISTRY
CN Phenol, 4-[[5-(1-methyl-1,7-diazaspiro[4.4]non-7-yl)-3-pyridinyl]oxy]-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-[5-(4-hydroxyphenoxy)-3-pyridyl]-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C19 H23 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 35 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN

RN **646056-31-7** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-[5-(cyclopentyloxy)-3-pyridinyl]-1-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-[5-(cyclopentyloxy)-3-pyridyl]-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C18 H27 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 36 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-30-6** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-methoxy-3-pyridinyl)-1-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C14 H21 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 37 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-29-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 38 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-28-2** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-pyrazinyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 39 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-27-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(1,3,4-oxadiazol-2-yl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-([1,3,4]oxadiazol-2-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H16 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 40 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-26-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(1,2,4-oxadiazol-5-yl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-([1,2,4]oxadiazol-5-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H16 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 41 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-25-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-isothiazolyl)-1-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H17 N3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 42 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-24-8** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-isoxazolyl)-1-methyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H17 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 43 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-23-7** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(5-pyrimidinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 44 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-22-6** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(3-Pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 45 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-21-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-pyrazinyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(2-Pyrazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 46 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-20-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(1,3,4-oxadiazol-2-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-([1,3,4]Oxadiazol-2-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 47 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-19-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(1,2,4-oxadiazol-5-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-([1,2,4]Oxadiazol-5-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 48 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-18-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(5-isothiazolyl)- (9CI)** (CA INDEX

NAME)
OTHER NAMES:
CN **1-(5-Isothiazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 49 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-17-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(5-isoxazolyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(5-Isoxazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 50 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-16-8** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(5-pyrimidinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(5-Pyrimidinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 51 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-15-7** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(6-methoxy-3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(6-Methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H18 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 52 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-14-6** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(6-chloro-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(6-Chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H16 Cl N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 53 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-13-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-ethynyl-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C14 H17 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 54 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-12-4** REGISTRY
CN Phenol, 4-[[5-(1,7-diazaspiro[4.4]non-7-yl)-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **7-[5-(4-Hydroxyphenoxy)-3-pyridyl]-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C18 H21 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 55 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-11-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-[5-(cyclopentyloxy)-3-pyridinyl]-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-[5-(Cyclopentyloxy)-3-pyridyl]-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C17 H25 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 56 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-10-2** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-methoxy-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H19 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 57 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-09-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridazinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(3-Pyridazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 58 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-08-8** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-pyrazinyl- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(2-Pyrazinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 59 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-07-7** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(1,3,4-oxadiazol-2-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-([1,3,4]Oxadiazol-2-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 60 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-06-6** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(1,2,4-oxadiazol-5-yl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-([1,2,4]Oxadiazol-5-yl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C9 H14 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 61 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-05-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-isothiazolyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Isothiazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 62 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-04-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-isoxazolyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Isoxazolyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C10 H15 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 63 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-03-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-pyrimidinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Pyrimidinyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C11 H16 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 64 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-02-2** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-1-[(2S)-2-pyrrolidinylcarbonyl]-, (5S)- (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H24 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 65 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-01-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-1-[(2S)-2-pyrrolidinylcarbonyl]-, (5R)- (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H24 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 66 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646056-00-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-, (-)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(-)-7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane**
FS STEREOSEARCH
MF C12 H17 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 67 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-99-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-, (+)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(+)-7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane**
FS STEREOSEARCH
MF C12 H17 N3

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 68 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-74-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(5-phenoxy-3-pyridinyl)-, dihydrochloride (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane dihydrochloride**
MF C19 H23 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (646055-71-2)



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 69 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-73-4** REGISTRY

CN **1,7-Diazaspiro[4.4]nonane, 7-(5-phenoxy-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C18 H21 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 70 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-72-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-phenoxy-3-pyridinyl)-1-(phenylmethyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Benzyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C25 H27 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 71 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-71-2** REGISTRY

CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(5-phenoxy-3-pyridinyl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C19 H23 N3 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 72 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-70-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-ethoxy-3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(5-Ethoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C14 H21 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 73 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN

RN **646055-69-8** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-ethoxy-3-pyridinyl)-1-(phenylmethyl)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Benzyl-7-(5-ethoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C21 H27 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 74 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-68-7** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(5-ethoxy-3-pyridinyl)-1-methyl-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(5-ethoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C15 H23 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 75 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN

RN **646055-67-6** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H17 N3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 76 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-66-5** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-methyl-7-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Methyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C13 H19 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 77 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN

RN **646055-65-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C12 H17 N3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 78 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-64-3** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane-7-carboxylic acid, 1-(3-pyridinyl)-, 1,1-dimethylethyl ester (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **tert-Butyl 6-(3-pyridyl)-2,6-diazaspiro[4.4]nonane-2-carboxylate**
FS 3D CONCORD
MF C17 H25 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 79 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-63-2** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane-7-carboxylic acid, 1,1-dimethylethyl ester (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **tert-Butyl 2,6-diazaspiro[4.4]nonane-2-carboxylate**
FS 3D CONCORD
MF C12 H22 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 80 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-62-1** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane-7-carboxylic acid, 1-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **tert-Butyl 6-benzyl-2,6-diazaspiro[4.4]nonane-2-carboxylate**
FS 3D CONCORD
MF C19 H28 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 81 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-61-0** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(3-pyridinyl)-, dihydrochloride (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane dihydrochloride**
MF C12 H17 N3 . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (646055-65-4)



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 82 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-60-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(phenylmethyl)-7-(3-pyridinyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Benzyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C19 H23 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 83 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **646055-57-4** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 7-(3-pyridinyl)-, dihydrochloride (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **7-(3-Pyridyl)-1,7-diazaspiro[4.4]nonane dihydrochloride**
MF C12 H17 N3 . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (646055-67-6)



●2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 84 OF 84 REGISTRY COPYRIGHT 2004 ACS on STN
RN **128244-01-9** REGISTRY
CN **1,7-Diazaspiro[4.4]nonane, 1-(phenylmethyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **1-Benzyl-1,7-diazaspiro[4.4]nonane**
FS 3D CONCORD
MF C14 H20 N2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



compd of applicant

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 14:47:31 ON 22 SEP 2004)

FILE 'REGISTRY' ENTERED AT 14:47:42 ON 22 SEP 2004

FILE 'CAPLUS' ENTERED AT 14:47:47 ON 22 SEP 2004
L1 1 S US20040067930/PN
SELECT RN L1 1

FILE 'REGISTRY' ENTERED AT 14:48:28 ON 22 SEP 200